Myeloproliferative Neoplasms (MPN)

Latest News

The iRR6 may help identify those who are unlikely to derive long-term benefit from ruxolitinib and could be considered for alternative therapies. | Image credit: mdaros - stock.adobe.com
Refined iRR6 Model Improves Risk Stratification in Intermediate-1 Myelofibrosis

September 12th 2025

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

Further research into the interplay between bone marrow, pulmonary vasculature, and cardiac function could help develop novel therapeutic strategies that could benefit both MPNs and cardiovascular disease. | Image credit: Tima - stock.adobe.com
MPNs May Increase Risk of Nonthrombotic Cardiovascular Conditions

August 21st 2025

The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com
AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

August 14th 2025

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com
QRISK3 Tool Predicts Thrombotic Events in ET, PV

August 8th 2025

The researchers emphasized the importance of preventing bleeding events through personalized use of antiplatelet or cytoreductive therapies and closer monitoring of high-risk patients. | Image credit: Matthieu - stock.adobe.com
Hemorrhagic Events After Essential Thrombocythemia Diagnosis Strongly Linked to Early Death

July 29th 2025

More News

Neutrophil | Image: Blausen Medical 2014
November 14th 2024

Studies Highlight Prognostic Value of Neutrophil-to-Lymphocyte Ratio in MPNs

Mary Caffrey
The key driver in both sets of findings is the relationship between neutrophils and inflammation.
MPN Congress logo | Image Credit: 16th International Congress on Myeloproliferative Neoplasms
November 9th 2024

Lower Pharmacy Costs Give Ruxolitinib Edge for Patients With MF and Anemia

Mary Caffrey
Authors found the pharmacy costs for momelotinib were $11,095 higher per month, too much to offset higher transfusion costs for ruxolitinib.
Screenshot of an interview with Ruben Mesa, MD
November 3rd 2024

The Importance of Symptomatic Improvement in MPN

Laura Joszt, MA Mary Caffrey
Symptomatic improvement on therapy for myeloproliferative neoplasms (MPNs) is very much based on the individual. Data does show momelotinib not only improved spleen size and anemia but also improved symptomatic burden.
3D illustration of heart | Image Credit: yodiyim - stock.adobe.com
November 2nd 2024

Age, Race, Insurance Status Can Predict CV Mortality for Those With MPNs

Mary Caffrey
Being married and having insurance can offer emotional support and financial stability to lead to early diagnosis and effective treatment, the authors found.
Ruben Mesa, MD
October 30th 2024

Treatment Differences for Younger vs Older Patients With MPNs

Laura Joszt, MA Mary Caffrey
Therapy selection for younger patients with myeloproliferative neoplasms (MPNs) may be different based on the desire for fertility preservation, but they are also at greater risk of their disease progressing, explained Ruben Mesa, MD, FACP, of Atrium Health.
Polycythemia Vera | Image credit: Elizabeth L. Courville, MD, for ASH Image Bank
October 25th 2024

Exploring Possibilities in Disease Modification in MPNs

Mary Caffrey
Experts are asking whether the study and treatment of myeloproliferative neoplasms (MPNs) is ready for a new era with new end points, with data that show how survival benefits are biologically linked to changes in the spleen, reduction in fibrosis, or other responses.
Screenshot of an interview with Ruben Mesa, MD
October 24th 2024

Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges

Mary Caffrey Laura Joszt, MA
There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Jakafi | Image: Novartis
October 14th 2024

Update: Ruxolitinib Beats Best Available Therapy in Treating Polycythemia Vera

Mary Caffrey
Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other treatments for polycythemia vera.
Aaron Gerds, MS, MS | Image credit: Cleveland Clinic
October 11th 2024

NCCN Guidelines for MPN Reflect New Drugs, Focus on Clinical Trials

Interview by Mary Caffrey
An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of myeloproliferative neoplasms (MPN) calls puts a priority on clinical trials, even preferring them to FDA-approved therapies in some cases. Aaron Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute discusses the updates and what's in the pipeline for MPN treatment.
Rivaroxaban | Image: Janssen
September 25th 2024

Korean Study Finds DOAC Use “Seems Effective” in Patients With MPNs

Mary Caffrey
A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.
Can Vaccines Be Developed for MPNs? Study Examines the Challenges
September 18th 2024

Can Vaccines Be Developed for MPNs? Study Examines the Challenges

Mary Caffrey
Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for patients from their country with an international data set.
Bone marrow from patient with PMF
September 12th 2024

Review Explores Cardiovascular Risk in Certain Patients With MPNs

Mary Caffrey
Inflammation and genetic mutations can drive cardiovascular complications in patients with myeloproliferative neoplasms, which include disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Myelofibrosis | Image credit: ASH Image bank
September 5th 2024

In Myelofibrosis, Ruxolitinib Before and After Allo-HSCT May Improve Success Rate

Mary Caffrey
A review by authors from China examines evidence involving different treatment approaches.
Three DNA strands on a blue background | Image credit: Hypnosis - stock.adobe.com
April 25th 2024

Lack of Mutations Associated With Favorable Prognosis in MPN-U

Laura Joszt, MA
While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Raajit Rampal, MD, PhD, screenshot
April 20th 2024

New Data Challenge Traditional Treatment Paradigm in MPNs, Says Dr Raajit Rampal

Laura Joszt, MA
Traditionally, low-risk patients with myeloproliferative neoplasms (MPNs) are not given medication, but new data challenge that thinking, said Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center.
White piggy bank next to a pink stethoscope and various health care icons | Image credit: Kiattisak - stock.adobe.com
April 12th 2024

Utilization of Momelotinib for Myelofibrosis With Anemia Can Result in Small Savings

Laura Joszt, MA
The introduction of momelotinib to treat myelofibrosis with anemia can result in small savings due to reduced transfusion-related costs, according to a budget impact model.
Raajit Rampal, MD, PhD, screenshot
April 7th 2024

Dr Raajit Rampal Discusses Disease Modification and Emerging Therapies in Polycythemia Vera

Laura Joszt, MA
Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the potential of a disease-modifying therapy in polycythemia vera, treating high-risk vs low-risk patients, and emerging therapies in the pipeline.
Patient meeting with physician Image credit: buritora - stock.adobe.com
April 6th 2024

Follow-Up Needs for Blood Cancer Survivors May Determine Best Type of Provider

Laura Joszt, MA
Differing characteristics of the patient and their disease may mean certain providers—academic oncologists, community oncologists, and primary care physicians—may be best suited for follow-up care.
Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center
April 1st 2024

Emerging Data Continue to Evolve Treatment Utilization in MPNs

Laura Joszt, MA
Despite being used for decades, there continues to be emerging data on interferons and how they should be used in patients with myeloproliferative neoplasms (MPNs), explains Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center.
Polycythemia vera blood cells | Image credit: Dr_Microbe - stock.adobe.com
March 27th 2024

Younger Patients With PV May Benefit From Earlier Treatment With Cytoreductive Therapies

Laura Joszt, MA
For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.
Blood sample for Myeloproliferative disorders panel | Image Credit: MdBabul - stock.adobe.com
March 26th 2024

Pegylated Interferons Have Promise but Also Unmet Potential in MPNs

Jared Kaltwasser
Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs).
Screenshot of Raajit Rampal, MD, PhD
March 22nd 2024

Dr Raajit Rampal Highlights Emerging Therapies in MPNs

Laura Joszt, MA
Interferons have been a major treatment for myeloproliferative neoplasms (MPNs) for decades, but emerging therapies are expanding the treatment armamentarium, explained Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center.
Primary myelofibrosis cells | Image credit: LASZLO - stock.adobe.com
March 16th 2024

Disease-, Age-, Genomic-Specific Factors Increase Risk of ET, PV, PrePMF Developing Into Overt MF

Laura Joszt, MA
New research highlights the factors that increase the likelihood that essential thrombocytopenia (ET), polycythemia vera (PV), and prefibrotic primary myelofibrosis (PrePMF) will evolve into overt myelofibrosis (MF).
Polycythemia vera red blood cells | Image credit: Dr_Microbe - stock.adobe.com
March 13th 2024

Patients With MPNs Have Increased Risk of Thrombosis, Hemorrhage, Leukemic Transformation

Laura Joszt, MA
Compared with matched controls, patients with myeloproliferative neoplasms (MPNs) had a higher risk of developing thrombosis, hemorrhage, and leukemic transformation, according to a longitudinal cohort study.
Distressed young woman of color | Image credit: Diego Cervo - stock.adobe.com
March 8th 2024

AYA With MPN Face Psychological Needs That Are Poorly Understood

Laura Joszt, MA
A review of research confirms that adolescents and young adults (AYA) with myeloproliferative neoplasms (MPN) face psychological burdens but the exact burden is poorly understood.
National Comprehensive Cancer Network (NCCN) logo | Image credit: NCCN
March 6th 2024

NCCN Lists Ropeginterferon Alfa-2B as Preferred First-Line Cytoreductive Therapy for Polycythemia Vera

Ashling Wahner
The National Comprehensive Cancer Network (NCCN) recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
March 1st 2024

Dr Jennifer Vaughn: Patients With MPN, MDS Should Discuss Long-Term Priorities Upfront

Laura Joszt, MA Justina Petrullo
For many patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS), their disease will be chronic, giving them a long-term cancer experience, said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
Doctor Measuring arterial blood pressure man patient Health care in hospital | joyfotoliakid - stock.adobe.com
December 7th 2023

Reducing Cardiovascular Risk in Patients With Polycythemia Vera

Pearl Steinzor
Polycythemia vera (PV) therapy should aim to identify cardiovascular risk factors, according to one review.
Diagnosis of Myelofibrosis. Laboratory blood bottle (tube), glass slide with blood smear, hematology test, stethoscope lying on notebook with printed text hematological diagnosis of Myelofibrosis | shidlovski - stock.adobe.com
November 17th 2023

Enhancing Outcomes and Quality of Life for Patients With Myelofibrosis

Pearl Steinzor
A phase 3 trial in symptomatic and anemic patients with myelofibrosis (MF) met its primary end point, seeing a significant symptom reduction at 24 weeks with momelotinib vs danazol.
Rare diseases inscription words. Medical concept of unusual disorders | valiantsin - stock.adobe.com
October 24th 2023

The Effects of Aging on Profiling Epigenetic Changes in Myeloproliferative Neoplasms

Pearl Steinzor
Researchers identified distinct patterns of epigenetic dysregulation in myeloproliferative neoplasms.
<123>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo